Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

NCT00093704 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped study could not recruit any more patients

Conditions

Lymphoma
Lymphoproliferative Disorder

Interventions

DRUG: bortezomib + ganciclovir

Sponsor

Jonsson Comprehensive Cancer Center